Federal grants to Max Biopharma, Inc
Max Biopharma, Inc in Santa Monica, California received $4.1 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Diabetes, Digestive, and Kidney Diseases Extramural Research, with $1.8 million. It had no new grant money in fiscal 2025.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$4.1 million
- Awards4
- Awarded in FY 2025$0
- Largest award$1.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $855,153 |
| FY 2022 | 3 | $1.5 million |
| FY 2023 | 1 | $896,990 |
| FY 2024 | 1 | $889,701 |
| FY 2025 | 0 | $0 |
Programs that fund Max Biopharma, Inc
| Program | Awards | Amount |
|---|---|---|
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $1.8 million |
| Arthritis, Musculoskeletal and Skin Diseases Research | 1 | $1.7 million |
| Cardiovascular Diseases Research | 2 | $638,813 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $4.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, OXY210, as a therapeutic drug candidate for non-alcoholic steatohepatitis - abstract pathologic tissue fibrosis, impelled by uncontrolled wound healing responses to acute or chronic injury is a significant problem in many or | Diabetes, Digestive, and Kidney Diseases Extramural Research | April 24, 2023 | $1.8 million |
| Therapeutic development of osteogenic oxysterol, OXY133, for spine fusion - abstract spine fusion is often the procedure of choice for various spine conditions, including degenerative spine, trauma, tumors and deformities. The goal of the procedure is to bridge the defect by filling the void and pro | Arthritis, Musculoskeletal and Skin Diseases Research | August 31, 2021 | $1.7 million |
| Effect of a semi-synthetic oxysterol drug candidate, OXY210, on atherosclerosis in a mouse model of nash - abstract cardiovascular disease (CVD) remains the leading cause of death in the united states and worldwide. The large majority of cvd-related deaths are the direct result of atherosclerosis an | Cardiovascular Diseases Research | May 23, 2022 | $320,724 |
| An oxysterol drug candidate, OXY210, for inhibition of pulmonary fibrosis through targeting hedgehog and tgf? Signaling - abstract idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease, characterized by progressive, irreversible scarring of lung tissue and declining lung functio | Cardiovascular Diseases Research | August 9, 2022 | $318,089 |
Questions people ask
How much federal grant money does Max Biopharma, Inc get?
$4.1 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Max Biopharma, Inc the most?
The Department of Health and Human Services, with $4.1 million in 4 awards.
What is Max Biopharma, Inc's largest federal grant?
$1.8 million under Diabetes, Digestive, and Kidney Diseases Extramural Research, with its first action in the period on April 24, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Max Biopharma, Inc?
Its largest are Diabetes, Digestive, and Kidney Diseases Extramural Research, Arthritis, Musculoskeletal and Skin Diseases Research and Cardiovascular Diseases Research.
Other grant recipients in Santa Monica
- The Rand Corporation
- City of Santa Monica
- Santa Monica Community College District
- Santa Monica Community College District
- National Institute for Excellence in Teaching
- Radiabeam Technologies, LLC
- City of Santa Monica
- Step Up on Second Street, Inc.
Largest federal grant recipients in California · Federal grants in California